NCT06658405 2026-03-18
HPV2
Centre Oscar Lambret
Phase 2 Recruiting
Clinical Trials
213 trialsNCT00420563 2026-03-16
PAL-ANGI
Centre Oscar Lambret
Phase 2 Completed
NCT05993299 2026-03-11
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT04449549 2026-03-09
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06979596 2026-03-06
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT06807593 2026-03-05
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05148078 2026-03-02
Pediatric Radiation Oncology With Movie Induced Sedation Effect (PROMISE)
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT06435286 2026-03-02
Effectiveness and Performance of an Optical Biopsy Technology for Esophageal Cancer in Brazil and the United States
Baylor College of Medicine
Phase 2 Recruiting
NCT06703346 2026-02-25
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT05879146 2026-02-19
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03388190 2026-02-13
METIMMOX
University Hospital, Akershus
Phase 2 Completed
NCT06593522 2026-02-05
A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
Amgen
Phase 2 Recruiting
NCT06417190 2026-02-04
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT06788938 2026-02-02
Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT07381231 2026-02-02
I-APT
Samsung Medical Center
Phase 2 Recruiting
NCT07378761 2026-01-30
CHILURSO
University Hospital, Montpellier
Phase 2 Not yet recruiting
NCT06323473 2026-01-23
Maitake
The Canadian College of Naturopathic Medicine
Phase 2 Recruiting
NCT07356791 2026-01-21
REBIRTH-013
RenJi Hospital
Phase 2 Not yet recruiting
NCT06201884 2026-01-12
APPAHOCA-2
Centre Francois Baclesse
Phase 2 Recruiting
NCT07126561 2026-01-08
Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers
University of Chicago
Phase 2 Not yet recruiting
NCT04795661 2026-01-07
IMHOTEP
Centre Leon Berard
Phase 2 Active not recruiting
NCT06162351 2026-01-02
TOPOLOGY
Institut Curie
Phase 2 Terminated
NCT04847466 2025-12-24
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT07284589 2025-12-16
Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake
Nuclear Imaging Institute
Phase 2 Recruiting
NCT06107413 2025-12-12
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
AbbVie
Phase 2 Active not recruiting
NCT07279532 2025-12-12
Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT04570943 2025-12-05
GABRINOX-ART
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Recruiting
NCT05867615 2025-12-03
LUBASKET
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Active not recruiting
NCT04452955 2025-12-02
A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors
Intra-IMMUSG Pte Ltd
Phase 2 Active not recruiting
NCT01697527 2025-11-24
Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04819373 2025-11-12
BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors
Eikon Therapeutics
Phase 2 Completed
NCT04181463 2025-10-31
Nasal Inhalation of Isopropyl Alcohol for the Treatment of Nausea in Patients With Cancer
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT05405413 2025-10-20
CATRINA
Dartmouth-Hitchcock Medical Center
Phase 2 Recruiting
NCT03755895 2025-10-03
HYCUDES
Institut de Cancérologie de Lorraine
Phase 2 Completed
NCT04614480 2025-09-22
EXOMA2
Centre Georges Francois Leclerc
Phase 2 Recruiting
NCT06175221 2025-09-15
Autologous TLPO Vaccine Basket
Elios Therapeutics, LLC
Phase 2 Terminated
NCT03310879 2025-09-02
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07000162 2025-08-29
LART
Azienda USL Reggio Emilia - IRCCS
Phase 2 Recruiting
NCT02304809 2025-08-01
AcSé
UNICANCER
Phase 2 Active not recruiting
NCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT06010342 2025-07-22
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
Teligene US
Phase 2 Recruiting
NCT07077564 2025-07-22
SKB264-II-NEN
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT06926673 2025-07-03
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3
GlaxoSmithKline
Phase 2 Completed
NCT07041788 2025-06-27
Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC
Second Affiliated Hospital of Nanchang University
Phase 2 Not yet recruiting
NCT06936748 2025-06-17
SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors
Second Affiliated Hospital of Nanchang University
Phase 2 Not yet recruiting
NCT00505063 2025-06-15
Prospective Trial of Vaccine Responses in Childhood Cancer Survivors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT06559228 2025-06-15
ConnectedNest: a Digital Platform Connecting Individuals With Cancer to Social Care
University of Minnesota
Phase 2 Recruiting
NCT03847649 2025-06-11
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT07002502 2025-06-10
Immune Modulation With PRaG-1 Treatment
Second Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
NCT03089554 2025-06-06
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
University of Kentucky
Phase 2 Recruiting